Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses DOI Creative Commons
Felicitas Ruiz, William Foreman, Michelle M. Lilly

et al.

PLoS Pathogens, Journal Year: 2024, Volume and Issue: 20(10), P. e1012650 - e1012650

Published: Oct. 28, 2024

The recurring spillover of pathogenic coronaviruses and demonstrated capacity sarbecoviruses, such SARS-CoV-2, to rapidly evolve in humans underscores the need better understand immune responses this virus family. For purpose, we characterized functional breadth potency antibodies targeting receptor binding domain (RBD) spike glycoprotein that exhibited cross-reactivity against SARS-CoV-2 variants, SARS-CoV-1 sarbecoviruses from diverse clades animal origins with potential. One neutralizing antibody, C68.61, showed remarkable neutralization both variants viruses different sarbecovirus clades. which targets a conserved RBD class 5 epitope, did not select for escape or culture nor have predicted among circulating strains, suggesting epitope is functionally constrained. We identified 11 additional SARS-CoV-2/SARS-CoV-1 cross-reactive target more sequence 4 epitopes within show activity subset one antibody every single tested. A these Fc-mediated effector functions as potent impact infection outcome models. Thus, our study regions across may serve therapeutics pandemic preparedness well blueprints design immunogens capable eliciting cross-neutralizing responses.

Language: Английский

Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon DOI
Mehdi Benlarbi,

Dell-Dylan Kenfack,

Katrina Dionne

et al.

Virology, Journal Year: 2025, Volume and Issue: 605, P. 110467 - 110467

Published: Feb. 25, 2025

Language: Английский

Citations

0
Multiple Exposures to SARS-CoV-2 Spike enhance Cross-Reactive Antibody-Dependent Cellular Cytotoxicity against SARS-CoV-1 DOI
Guillaume Beaudoin-Bussières, Alexandra Tauzin,

Katrina Dionne

et al.

Virology, Journal Year: 2025, Volume and Issue: 607, P. 110512 - 110512

Published: March 22, 2025

Language: Английский

Citations

0
Molecular Basis of High-Blood-Pressure-Enhanced and High-Fever-Temperature-Weakened Receptor-Binding Domain/Peptidase Domain Binding: A Molecular Dynamics Simulation Study DOI Open Access
Xubin Xie, Yu Shrike Zhang, Ying Fang

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3250 - 3250

Published: March 31, 2025

The entry and infection of the Severe Acute Respiratory Syndrome Coronavirus 2 virus (SARS-CoV-2) involve recognition binding receptor-binding domain (RBD) surface spike protein to peptidase (PD) host cellular Angiotensin-Converting Enzyme-2 (ACE2) receptor. ACE2 is also involved in normal blood pressure control. An association between hypertension COVID-19 severity fatality evident, but how predisposes patients diagnosed with unfavorable outcomes remains unclear. High temperature early during SARS-CoV-2 impairs human cells retards viral progression. Low body can prelude poor prognosis. In this study, all-atom molecular dynamics simulations were performed examine effects high on RBD/PD binding. A 940 mmHg enhanced above 315 K significantly weakened binding, while a low 305 curvature PD α1-helix proximity β3β4-hairpin tip RBM motif affected compactness interface and, hence, affinity. These findings provide novel insights into underlying mechanisms by which an initial

Language: Английский

Citations

0
Will COVID-19 become mild, like a cold? DOI Creative Commons
Patrick D. Shaw Stewart

Epidemiology and Infection, Journal Year: 2024, Volume and Issue: 152

Published: Jan. 1, 2024

Abstract Several recent studies conclude that an increase in the pathogenicity of SARS-CoV-2 cannot be ruled out. However, it should noted is a ‘direct’ respiratory virus – meaning usually spread by route but does not routinely pass through lymphatics like measles and smallpox. Providing its tropism change, will unique if decrease until becomes similar to common cold viruses. Ewald 1980s viruses may evolve mildness because their benefits from mobility hosts. This review examines factors lower viruses’ severity, including heat sensitivity (which limits replication warmer lungs) changes virus’s surface proteins. Other may, however, pathogenicity, such as lymphatic system spreading via solid surfaces or faecal matter. Furthermore, human activities political events could harmfulness SARS-CoV-2, following: large-scale testing, especially when results are delayed; transmission settings where people close together free move around; poor hygiene facilities; social, political, cultural influences encourage sick individuals remain active, crises wars. If we can avoid these eventualities, likely milder, although timescale uncertain. Observations influenza-like pandemics suggest take around two decades for COVID-19 become mild seasonal colds.

Language: Английский

Citations

0
Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses DOI Creative Commons
Felicitas Ruiz, William Foreman, Michelle M. Lilly

et al.

PLoS Pathogens, Journal Year: 2024, Volume and Issue: 20(10), P. e1012650 - e1012650

Published: Oct. 28, 2024

The recurring spillover of pathogenic coronaviruses and demonstrated capacity sarbecoviruses, such SARS-CoV-2, to rapidly evolve in humans underscores the need better understand immune responses this virus family. For purpose, we characterized functional breadth potency antibodies targeting receptor binding domain (RBD) spike glycoprotein that exhibited cross-reactivity against SARS-CoV-2 variants, SARS-CoV-1 sarbecoviruses from diverse clades animal origins with potential. One neutralizing antibody, C68.61, showed remarkable neutralization both variants viruses different sarbecovirus clades. which targets a conserved RBD class 5 epitope, did not select for escape or culture nor have predicted among circulating strains, suggesting epitope is functionally constrained. We identified 11 additional SARS-CoV-2/SARS-CoV-1 cross-reactive target more sequence 4 epitopes within show activity subset one antibody every single tested. A these Fc-mediated effector functions as potent impact infection outcome models. Thus, our study regions across may serve therapeutics pandemic preparedness well blueprints design immunogens capable eliciting cross-neutralizing responses.

Language: Английский

Citations

0